Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CRIS Curis Inc
- Stocks
- Healthcare
- NASDAQ: CRIS
Price (delayed)
$1.81
Market cap
$18.94M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.09
Enterprise value
$1.29M
Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of
Highlights
Curis's EPS has increased by 30% YoY and by 11% QoQ
The gross profit has grown by 16% YoY and by 3% from the previous quarter
CRIS's debt is down by 11% from the previous quarter but it is up by 6% YoY
The equity has plunged by 170% YoY and by 10% from the previous quarter
CRIS's quick ratio has dropped by 70% year-on-year and by 9% since the previous quarter
Key stats
What are the main financial stats of CRIS
Market
Valuations
Earnings
Shares outstanding
10.46M
Market cap
$18.94M
Enterprise value
$1.29M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.12
Revenue
$11.2M
Gross profit
$11.14M
Operating income
-$42.23M
Net income
-$42.13M
EBIT
-$42.13M
EBITDA
-$40.71M
Free cash flow
-$33.58M
Per share
Balance sheet
Liquidity
EPS
-$6.09
EPS diluted
-$6.09
Free cash flow per share
-$3.95
Book value per share
-$0.78
Revenue per share
$1.32
TBVPS
$3.57
Total assets
$39.33M
Total liabilities
$45.93M
Debt
$2.64M
Equity
-$6.61M
Working capital
$4.69M
Debt to equity
-0.4
Current ratio
1.23
Quick ratio
1.12
Net debt/EBITDA
0.43
Margins
Efficiency
Dividend
EBITDA margin
-363.4%
Gross margin
99.4%
Net margin
-376.1%
Operating margin
-377%
Return on assets
-97.1%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-219.3%
Return on sales
-376.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRIS stock price
How has the Curis stock price performed over time
Intraday
3.43%
1 week
-18.47%
1 month
-21.3%
1 year
-71.04%
YTD
-40.85%
QTD
-21.98%
Financial performance
How have Curis's revenue and profit performed over time
Revenue
$11.2M
Gross profit
$11.14M
Operating income
-$42.23M
Net income
-$42.13M
Gross margin
99.4%
Net margin
-376.1%
CRIS's operating margin is up by 25% year-on-year and by 8% since the previous quarter
CRIS's net margin is up by 23% YoY and by 5% from the previous quarter
The gross profit has grown by 16% YoY and by 3% from the previous quarter
The revenue has increased by 14% year-on-year and by 2.7% since the previous quarter
Price vs fundamentals
How does CRIS's price correlate with its fundamentals
Growth
What is Curis's growth rate over time
Valuation
What is Curis stock price valuation
P/E
N/A
P/B
N/A
P/S
1.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.12
Curis's EPS has increased by 30% YoY and by 11% QoQ
The equity has plunged by 170% YoY and by 10% from the previous quarter
CRIS's price to sales (P/S) is 94% lower than its 5-year quarterly average of 21.3 and 47% lower than its last 4 quarters average of 2.6
The revenue has increased by 14% year-on-year and by 2.7% since the previous quarter
Efficiency
How efficient is Curis business performance
The company's return on assets has shrunk by 59% YoY and by 10% QoQ
Curis's return on sales has increased by 23% YoY and by 5% QoQ
Dividends
What is CRIS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRIS.
Financial health
How did Curis financials performed over time
The company's total assets is 14% lower than its total liabilities
The current ratio has dropped by 70% year-on-year and by 12% since the previous quarter
CRIS's quick ratio has dropped by 70% year-on-year and by 9% since the previous quarter
CRIS's debt is 140% more than its equity
The equity has plunged by 170% YoY and by 10% from the previous quarter
The debt to equity has increased by 18% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.